# Phase 2 Crohn Disease trials recruiting: 30 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials in phase 2 for Crohn Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Crohn Disease trials: 30 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/crohn-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 30
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 13, 2026 | NCT07871669 | Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | Phase 2 | Not yet recruiting | Enteric Hyperoxaluria | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871669) |
| September 22, 2026 | NCT07832435 | A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures | Redx Pharma Ltd | Phase 2 | Not yet recruiting | Strictures Due to Crohn's Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832435) |
| August 10, 2026 | NCT07753850 | A Study of SL-325 in Crohn's Disease Patients | Shattuck Labs, Inc. | Phase 2 | Recruiting | Crohn's Disease | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753850) |
| July 13, 2026 | NCT07697456 | Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis | AbbVie | Phase 2 | Recruiting | Crohn's Disease, Ulcerative Colitis | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697456) |
| June 30, 2026 | NCT07677514 | A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease | Jiangsu Carephar Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Crohn's Disease | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677514) |
| June 4, 2026 | NCT07625293 | DB-3Q for the Treatment of Medically Refractory Crohn's Disease | Direct Biologics, LLC | Phase 2 | Recruiting | Crohn Disease (CD) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625293) |
| March 19, 2026 | NCT07483099 | A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | Eli Lilly and Company | Phase 2 | Recruiting | Crohn Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483099) |
| March 19, 2026 | NCT07483073 | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | Eli Lilly and Company | Phase 2 | Recruiting | Colitis, Ulcerative, Crohn Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483073) |
| February 11, 2026 | NCT07403968 | A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease | Takeda | Phase 2 | Recruiting | Crohn's Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403968) |
| December 24, 2025 | NCT07300553 | Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease | Assistance Publique - Hôpitaux de Paris | Phase 2 | Recruiting | IBD, Crohn Disease, Ulcerative Colitis (UC) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300553) |
| December 22, 2025 | NCT07295834 | Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial | Imperial College London | Phase 2 | Not yet recruiting | Crohn Disease (CD), Ulcerative Colitis (UC), Fatigue | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295834) |
| November 10, 2025 | NCT07225998 | Oral N-acetylglucosamine in Crohn's Disease | Johns Hopkins University | Phase 2 | Not yet recruiting | Crohns Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225998) |
| August 8, 2025 | NCT07113522 | A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease | Mirador Therapeutics, Inc. | Phase 2 | Recruiting | Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07113522) |
| July 22, 2025 | NCT07078994 | Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to... | Biocad | Phase 2 | Recruiting | Crohn's Disease (CD) | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07078994) |
| July 22, 2025 | NCT07077746 | HB-adMSCs for the Treatment of Crohn's Disease | Hope Biosciences Research Foundation | Phase 2 | Recruiting | Crohn Disease (CD) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077746) |
| May 16, 2025 | NCT06976853 | Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Washington University School of Medicine | Phase 2 | Recruiting | Crohn Disease (CD) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976853) |
| May 6, 2025 | NCT06958536 | A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease | Sanofi | Phase 2 | Recruiting | Crohn's Disease | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06958536) |
| May 1, 2025 | NCT06953791 | Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients | University Hospital Tuebingen | Phase 2 | Recruiting | Crohn Disease, Nutrition Assessment, Diet Therapy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06953791) |
| April 13, 2025 | NCT06925061 | Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease | Sponsor not shown (see the record) | Phase 2 | Recruiting | Crohn Disease (CD) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925061) |
| January 8, 2025 | NCT06764615 | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) | Takeda | Phase 2 | Recruiting | Crohn's Disease, Ulcerative Colitis | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06764615) |
| October 8, 2024 | NCT06631586 | Standardized Microbiota Transplant Therapy in Crohn's Disease | University of Minnesota | Phase 2 | Recruiting | Crohn Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06631586) |
| August 12, 2024 | NCT06548542 | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease | AbbVie | Phase 2 | Recruiting | Crohn's Disease | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548542) |
| June 13, 2024 | NCT06456593 | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | Abivax S.A. | Phase 2 | Recruiting | Moderately to Severely Active Crohn Disease | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06456593) |
| January 31, 2024 | NCT06233461 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active... | Takeda | Phase 2 | Recruiting | Crohn's Disease | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06233461) |
| January 26, 2024 | NCT06226883 | A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Phase 2 | Recruiting | Inflammatory Bowel Diseases, Crohn's Disease | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226883) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 3 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| Jiangsu Carephar Pharmaceutical Co., Ltd. | 1 |
| Assistance Publique Hopitaux De Marseille | 1 |
| [Abivax S.A.](https://specstream.ai/data/clinical-trials/company/abivax-s-a) | 1 |
| Imperial College London | 1 |
| University Hospital Tuebingen | 1 |
| University of Minnesota | 1 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 1 |
| Johns Hopkins University | 1 |
| [Hope Biosciences Research Foundation](https://specstream.ai/data/clinical-trials/company/hope-biosciences-research-foundation) | 1 |
| Redx Pharma Ltd | 1 |
| Mirador Therapeutics, Inc. | 1 |
| [Biocad](https://specstream.ai/data/clinical-trials/company/biocad) | 1 |
| Washington University School of Medicine | 1 |
| Odense University Hospital | 1 |
| Direct Biologics, LLC | 1 |
| Shattuck Labs, Inc. | 1 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 1 |
| Rambam Health Care Campus | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 19 |
| France | 8 |
| Germany | 8 |
| Poland | 8 |
| Hungary | 7 |
| Canada | 7 |
| China | 6 |
| Belgium | 6 |
| Czechia | 6 |
| Italy | 6 |
| Israel | 6 |
| Slovakia | 5 |
| United Kingdom | 5 |
| Netherlands | 4 |
| Romania | 4 |
| Spain | 4 |
| Brazil | 4 |
| Japan | 4 |
| Taiwan | 4 |
| South Korea | 3 |
| Australia | 3 |
| Bulgaria | 3 |
| Denmark | 3 |
| Austria | 2 |
| Croatia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Aggregate suppliers in the United States](https://specstream.ai/data/businesses/aggregate-suppliers/united-states)
- [Personal injury law firms in the United States](https://specstream.ai/data/businesses/personal-injury-law-firms/united-states)
- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [B2B oil and gas exploration and development companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-exploration-and-development-companies/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
